Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 3 2Phase 2 1Phase 1/2 1Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2Inflammatory Breast Neoplasms 1

Interventions

Cyclophosphamide 149Docetaxel 138Paclitaxel 127Trastuzumab 119Tamoxifen 110Capecitabine 104Letrozole 92Epirubicin 79Doxorubicin 70Anastrozole 70exemestane 67Fulvestrant 65Fluorouracil 61Radiotherapy 60pertuzumab 40Gemcitabine 39Carboplatin 38Vinorelbine 34Goserelin 34Bevacizumab 29Zoledronic Acid 28Methotrexate 28Chemotherapy, Adjuvant 28eribulin 27Lapatinib 25ribociclib 24palbociclib 24Drug Therapy 22130-nm albumin-bound paclitaxel 20pegfilgrastim 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Breast Neoplasms × Microarray Analysis × Clear all
NCT00017095 2013-10-24

Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Completed
1,856 enrolled
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00070278 2013-08-07

Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
800 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡